Form 8-K Prime Medicine, Inc. For: Jul 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'
July 8, 2026 12:30 PM EDTTD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).
The analyst comments "PRME announced a positive binding arbitration resolution with BEAM over PM647 in AATD, confirming PM647 is in PRMEs field with no monetary damages. This removes a key investor overhang and clears the path for a Q3:26 filing, with initial data in 2027. We continue to view PRME as undervalued for the platforms potential. Buy. PRME announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, with the tribunal declaring that PM647 falls within PRMEs... More
